Palatin Technologies (@PalatinTech) header
Palatin Technologies (@PalatinTech) profile picture

We discover and develop novel therapeutics for patients living with inflammatory and autoimmune conditions. $PTN

Cranbury, NJ
Joined February 2013
Photo by Palatin Technologies (@PalatinTech)Photo by Palatin Technologies (@PalatinTech)Photo by Palatin Technologies (@PalatinTech)Photo by Palatin Technologies (@PalatinTech)Photo by Palatin Technologies (@PalatinTech)Photo by Palatin Technologies (@PalatinTech)Photo by Palatin Technologies (@PalatinTech)Photo by Palatin Technologies (@PalatinTech)Photo by Palatin Technologies (@PalatinTech)Photo by Palatin Technologies (@PalatinTech)
Palatin Reports Fiscal First Quarter 2027 Financial Results and Provides Business Update Read the Full Press Release 👉 palatin.com/press_releases/p… #PTN #PTNT #NYSE #OTCQB #News
1
92
Palatin Technologies Presents Compelling Preclinical Data on Next-Generation MC4R-Selective Peptide Agonists at ObesityWeek® 2026 Read the Full Press Release 👉 palatin.com/press_releases/p… #PTN #PTNT #NYSE #OTCQB #News
1
120
Palatin to Report First Quarter Fiscal Year 2027 Results Read the Full Press Release 👉 palatin.com/press_releases/p… #PTN #PTNT #NYSE #OTCQB #News
270
Palatin Reports Fiscal Year 2026 Financial Results and Provides Business Update Read the Full Press Release 👉 palatin.com/press_releases/p… #PTN #PTNT #NYSE #OTCQB #News
2
557
Palatin to Begin Trading on Nasdaq Stock Exchange Read the Full Press Release 👉 palatin.com/press_releases/p… #PTN #PTNT #NYSE #OTCQB #News
4
1
6
1,065
Palatin Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update Read the Full Press Release 👉 palatin.com/press_releases/p… #PTN #PTNT #NYSE #OTCQB #News
1
720
Palatin Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update Read the Full Press Release 👉 palatin.com/press_releases/p… #PTN #PTNT #NYSE #OTCQB #News
4
540
Palatin Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update Read the Full Press Release 👉 palatin.com/press_releases/p… #PTN #PTNT #NYSE #OTCQB #News
1
1
1
2
569
Palatin Technologies Announces Closing of Upsized $18.2 Million Public Offering with the Full Exercise of the Underwriters’ Over-Allotment Option Read the Full Press Release 👉 palatin.com/press_releases/p… #PTN #PTNT #NYSE #OTCQB #News
1
457
Palatin Presents Data at ObesityWeek® 2025 Highlighting Promise of Melanocortin-Based Therapies for Obesity Read the Full Press Release 👉 palatin.com/press_releases/p… #PTN #PTNT #NYSE #OTCQB #News
1
321
Palatin Technologies Announces Pricing of Upsized $15.8 Million Public Offering Read the Full Press Release 👉 palatin.com/press_releases/p… #PTN #PTNT #NYSE #OTCQB #News
1
1
274
Palatin Earns €5.5 Million ($6.5 Million) Milestone Payment in Retinal Disease Collaboration with Boehringer Ingelheim Read the Full Press Release 👉 palatin.com/press_releases/p… #PTN #PTNT #NYSE #OTCQB #News
1
1
5
453
Boehringer Ingelheim and Palatin Technologies to develop potential first-in-class melanocortin receptor targeted treatment for patients with retinal diseases Read the Full Press Release 👉 palatin.com/press_releases/b… #PTN #PTNT #NYSE #OTCQB #News
8
407
Palatin Announces 1-for-50 Reverse Stock Split Read the Full Press Release 👉 palatin.com/press_releases/p… #PTN #PTNT #NYSE #OTCQB #News
309
🚨 Breaking News 🚨: FDA confirms the acceptability of Palatin's Phase 3 trials for PL9643 in Dry Eye Disease! 🌟 Strong tolerability & safety profile. A major step forward in eye care innovation. Learn more: tinyurl.com/PalatinTech #DryEyeDisease #ClinicalTrials #Biotech
2
7
1,095
💡 Rapid & effective symptom relief for Dry Eye Disease is on the horizon! PL9643 is advancing through Phase 3 trials, bringing us closer to a new therapeutic option. Stay informed: tinyurl.com/PalatinTech #EyeCare #Innovation #PalatinTech #DED
1
1,008
🚀 Palatin Technologies kicks off a Phase 2 obesity study w/ Bremelanotide & Tirzepatide. Learn more: palatin.com/press_releases/f…
1
2
863
This study aims to advance obesity treatment by combining our MCR4 agonists with incretin therapeutics. #ObesityTreatment #ClinicalTrials #Biotech #HealthcareInnovation
1
765
🔥 Breaking: Palatin Technologies $PTN reveals positive results from our Phase 3 trial of PL9643 for Dry Eye Disease at ASCRS 2024! 🌐 Quick relief & excellent safety. Dive into the future of eye care with us! 🚀 #EyeHealth #Biotech palatin.com/press_releases/p…
766
$PTN Vyleesi® (bremelanotide injection) delivers its 7th consecutive quarter of double-digit growth in product revenue and prescriptions dispensed. Prescriptions grew 18% & net product revenue increased 14% over the prior quarter.  bit.ly/3ScqRe9
1,232